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Papillomaviruses (PV) bind to a wide range of cell lines in a specific and saturable manner. We have recently identified a
candidate receptor for papillomavirus as the a6 integrin (Evander et al., J. Virol. 71, 2449–2456, 1997). We have further
investigated the role the a6 integrin plays in PV binding. Here we show that the cells expressing the a6 integrin, partnered
with either the b4 integrin or the b1 integrin, are equally able to bind PV HPV6b L1 virus-like particles, indicating that the beta
partner does not play a major role in virus binding. In order to provide definitive evidence that the a6 integrin is required for
PV binding we undertook to genetically complement the receptor-negative B-cell line DG75 by expressing the human a6A
gene. The transduction of the a6 integrin gene into DG75 cells results in the cell surface expression of the a6 protein and
this expression confers upon DG75 cells the ability to bind laminin, a normal ligand for a6 integrin. Furthermore, the a6
protein is partnered with the b1 integrin in DG75 cells. Finally, we show that the DG75-a6 cells were able to bind
papillomavirus VLPs and this binding was inhibited by a functionally blocking anti-a6 antibody. Together these data indicate





























Papillomaviruses (PV) are nonenveloped dsDNA tumor
iruses that cause a range of proliferative lesions upon
nfection of epithelial cells (Howley, 1996). They infect a
ide range of species but exhibit a high degree of
pecies specificity (Shah and Howley, 1996). Over 70
ifferent human subtypes of PV have been isolated and
ormally described (de Villiers, 1994; Halpern et al., 1996),
ach infecting either mucosal or cutaneous epithelium at
istinct sites. For example, HPV11 infects mucosal epi-
helial cells of the genital tract but does not infect cuta-
eous epithelium from other body sites (Kreider et al.,
987). PVs are the causative agent of warts (plantar,
aryngopharyngeal, and genital) and are also the critical
actor in the formation of anogenital cancer (Zur Hausen,
994). The cancer-associated subtypes (HPV16, HPV18,
PV33, etc.) are termed high-risk, while all others are
ermed low-risk (Howley, 1996; Shah and Howley, 1996;
ur Hausen, 1994). Unfortunately, the lack of in vitro
eplication systems has meant that many critical aspects
f the virus life cycle remain unknown and therefore are
ot readily amenable to manipulation. However, the ad-
ent of virus-like particle technology has allowed some
spects of PV binding and internalization to be ad-
ressed.
1 To whom correspondence and reprint requests should be ad-
ressed at U.Q. Dept. of Medicine, PA Hospital, Ipswich Rd., Brisbane,
LD 4102 Australia. Fax: 161 7 32 40 59 46. E-mail: nmcmillan@wedicine.pa.uq.edu.au.
271The first step in viral infection is the binding of the
irus to a host cell. Previous reports have shown that
PV binds to a wide variety of cell lines to varying
egrees (Mu¨ller et al., 1995; Qi et al., 1996; Roden et al.,
994a; Volpers et al., 1995). However, the greatest bind-
ng was observed with epithelial and mesenchymal cells.
he PV particle is made of two proteins, L1 and L2. L1 is
he major coat protein, while L2 is thought to form a link
etween the viral DNA and the viral particle (Zhou et al.,
994, 1991). PV particles bound in a saturable manner,
ith 1–2 3 104 receptors/cell, while linear L1 protein
inding was nonsaturable (Qi et al., 1996). Binding was
rypsin-sensitive and this, along with the wide degree of
inding to cells from various species, suggests that the
eceptor is a widely conserved protein (Qi et al., 1996;
olpers et al., 1995). Furthermore, the same receptor
ppears to be utilized by all PVs for binding, as particles
rom one PV species or subtype will inhibit the binding of
nother (Mu¨ller et al., 1995; Roden et al., 1994a). For
xample, HPV6b inhibited the binding of HPV-11, -16, and
PV (Mu¨ller et al., 1995).
We have recently identified the a6 integrin as a can-
idate receptor for papillomavirus (Evander et al., 1997).
his finding was based on the observation that PV virus-
ike particles (VLPs) interacted with a protein consistent
n size with the a6 integrin and were able to be coim-
unoprecipatated with anti-a6 antibodies, and function-
lly blocking antibodies against a6 were able to reduce
LP binding to cells. Furthermore, a6 and VLP binding
ere colocalized upon the cell surface of the basal and
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272 MCMILLAN ET AL.uprabasal epithelial cells (the same cells to which viral
eplication is restricted) and the natural ligand for a6,
aminin, blocked VLP attachment. Finally, a binding-neg-
tive B-cell line, DG75, did not express the a6 integrin.
he a6 integrin is termed the epithelial integrin, as it is
xpressed most highly upon epithelial cells, the very
ame cell type that binds PVs to the highest degree and
ithin which primary infection is known to occur and to
hich vegetative DNA replication is restricted.
The a6 integrin partners with a beta integrin subunit,
ither b4 or b1. The a6b1 integrin is expressed on a
ide range of cells, including platelets, lymphocytes,
acrophages, oocytes, and endothelial cells, whereas
6b4 is relatively restricted to epithelial, mesenchy-
al, and some neuronal cells. In stratified squamous
pithelium the a6b4 complex is an integral part of the
emidesmosome (Sonnenberg et al., 1991) and as a
eceptor for laminins (Niessen et al., 1994) is involved
n the interaction of epithelial cells with the basement
embrane. The cells which have the highest degree of
V binding match the expression profile of a6b4, al-
hough PV does bind to cells expressing a6b1. Thus,
he expression of a6 is widespread and highly con-
erved between species, matching the criteria from
revious in vitro results.
We have previously proposed a model for PV infection
n which virus particles bind to the a6 integrin during
ound healing and are endocytosed during cell migra-
ion. The a6b4 integrin is believed to be attached to the
icrofilament network via the hemidesmosome (Gian-
otti et al., 1992; Spinardi et al., 1993) and this may
rovide an explanation for the observation that cytocha-
asin B inhibits papillomavirus uptake in CV-1 cells (Zhou
t al., 1995), suggesting that PV particles endocytosed
ogether with a6b4 integrin may be transported to the
ell nucleus via a microfilament-dependent pathway.
owever, while our data suggest that a6 is an HPV
eceptor it does not constitute definitive evidence that
his is the case. Therefore, we undertook to genetically
omplement the ability to bind HPV by expressing the a6
ene in the receptor-negative B-cell line DG75. First, we
how formally that PV binding occurs in cells that ex-
ress either a6b4 or a6b1. We demonstrate that the
ransduction of the a6 integrin gene into DG75 cells
esults in the cell surface expression of a6 protein and
hat this expression confers upon these cells the ability
o bind laminin, a normal ligand for a6 integrin. Further-
ore, the a6 protein is partnered with the b1 integrin in
G75 cells. Finally, DG75-a6 cells were able to bind PV
LPs and this binding was inhibited by a functionally
locking anti-a6 antibody. Together these data indicate
hat the a6 integrin is a primary cell receptor for papil-
omaviruses and is both necessary and sufficient for PV
inding. pRESULTS
inding of PV to cultured cell lines correlates with
xpression of a6 integrin
We have previously shown that HPV is able to bind
o cells that express the a6b4 integrin and that ligands
f, and antibodies against, a6 are able to block virus
inding, leading to the suggestion that a6b4 is the PV
eceptor. However, a6b4 has a limited tissue distribu-
ion (epithelial, mesenchymal, and some neuronal
ells), while HPV binding is known to occur in a wide
ariety of cells. The a6 integrin is able to heterodimer-
ze with two beta partners, b1 or b4. The a6b1 has a
ide tissue distribution, including platelets, lympho-
ytes, macrophages, oocytes, and endothelial cells.
hus, HPV may be able to bind to many cell types via
he a6b1 integrin. In order to test this possibility we
nalyzed two cell lines, COS-7 and HaCaT, which have
een reported to express a6b1 or a6b4 integrin, re-
pectively. We found that HaCaT cells express high
evels of a6, b1, and b4 integrin. It should be noted that
6 binds preferentially with b4 due to its higher affinity
or b4 than b1. As expected COS-7 cells express both
6 and b1 integrin but do not express b4 integrin (Fig.
A). We then tested these cells for their ability to bind
PV VLPs. Cells were exposed to VLPs at 4°C and
ashed, and VLPs detected using an L1-specific
onoclonal antibody. It can be seen that both HaCaT
nd COS-7 bind VLPs, while the receptor-negative cell
ine DG75 does not (Fig. 1B). This result indicates that
he beta partner does not appear to be important for
inding of VLPs but rather that it is the presence of a6
hat is required.
xpression of a6 integrin in DG75 cells
In order to prove that a6 is a critical factor required
or PV binding we undertook to genetically comple-
ent binding by transfecting the a6 gene into a cell
ine not able to bind PV. DG75 is a human B-cell line
hat does not express a6 integrin (Evander et al.,
997). The human a6A gene was cloned into the vector
BO-pLPP to allow high-level expression of the cloned
ene and maintenance in B-cells. Following transfec-
ion, cells were treated with hygromycin and resistant
ells pooled. Expression of a6A mRNA was demon-
trated by Northern blot analysis (data not shown) and
e confirmed that a6 protein was expressed and pro-
essed to the cell surface using flow cytometry (Fig. 2).
t can be seen that cells transfected with the a6 gene
DG75-a6) express moderate levels of a6 compared to
431-positive control cells, while cells transfected
ith the control plasmid (DG75-EBO-pLPP) expressed
o detectable a6 protein. We also ascertained the
xpression levels of the b1 and b4 integrins. Our
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273EXPRESSION OF THE a6 INTEGRIN CONFERS HPV BINDINGxpress b4 integrin so it was of interest to see if the
xpression of a6, which must partner with b1 in the
FIG. 1. Binding of HPV VLPs correlates with the expression of a6 inte
os-7 cells by flow cytometry. Filled profiles are positive, while empty
y immunoblotting for L1 protein. Cells were treated with (1) or withobsence of b4, would affect the level of b1 expression. pt can be seen that both DG75-EBO-pLPP and DG75-a6
ells expressed similar levels of b1 and neither ex-
) Analysis of the expression of a6, b1, and b4 integrins in HaCaT and
re the negative controls. (B) Binding of HPV6b VLPs to cells detected
LPs, incubated, washed, and L1 detected.grin. (A

























274 MCMILLAN ET AL.G75-a6 forms a heterodimer with b1 integrin
It is known that a6 heterodimerizes with either b1 or
4 integrin but partners preferentially with b4 in the
resence of both beta subunits (Klein et al., 1990). To
etermine how the a6 integrin expressed in DG75 cells
as acting we analyzed the integrin affiliation patterns
y labeling cell surface proteins from A431, DG75-EBO-
LPP, and DG75-a6 cells with 125I, preparing cell extracts,
nd subjecting them to immunoprecipitation using vari-
us anti-integrin antibodies (Fig. 3). The anti-a6 antibody
recipitated two major proteins of 120 and 220 kDa from
431 cells, consistent with the size of a6 and b4 inte-
rins. The anti-b1 antibody precipitated three proteins
etween 130 and 160 kDa, which most likely represent
he b1 (130 kDa), a2 (165 kDa), and a3 (130 kDa) inte-
rins. The DG75 cells transfected with the EBO-pLPP
lasmid alone had no specific proteins precipitated by
nti-a6, while the b1 antibody appeared to precipitate
FIG. 2. Analysis of the expression of a6, b1, and b4 integrins in DG
ositive, while empty peaks are the negative controls.wo bands of around 130 kDa (most likely b1 and a3). In pG75-a6 cells two proteins of 120 and 130 kDa were
recipitated by the anti-a6 antibody. This differs from
431 and DG75-EBO-pLPP cells and is consistent with
he flow cytometry data (Fig. 2) and indicates that a6 is
artnering with the b1 integrin in the absence of b4.
ls transfected with the a6A gene by flow cytometry. Filled peaks are
FIG. 3. Immunoprecipitation of 125I-labeled integrins from cells. Cell


























































275EXPRESSION OF THE a6 INTEGRIN CONFERS HPV BINDINGG75-a6 binds laminin
We wished to determine if the a6 we had expressed in
G75 cells was functional and able to bind to its natural
igand, laminin. The a6b4 integrin is normally expressed
n epithelial cells and functions as a receptor for laminin
(although it binds laminin 1 with low affinity), whereas
6b1 is expressed in a wider variety of cells types
platelets, lymphocytes, macrophages, oocytes, and en-
othelial cells) and has been reported to bind to laminins
, 2, 4, and 5 (Niessen et al., 1994). B-cells such as DG75
xpress a2b1 and a3b1, which bind to collagen and
ibronectin, respectively, although both these integrins
re reported to bind laminin with low affinity depending
n what cell type they are expressed in (Ziober et al.,
996). We undertook cell adhesion assays using DG75-
BO-pLPP and DG75-a6 cells and tested their ability to
ind to laminin-coated plates as previously described
Chao et al., 1996). It can be seen that the a6-expressing
G75 cells were able to bind well at all concentrations of
aminin tested (Fig. 4). Control cells, however, were un-
ble to bind laminin to any great degree, although as the
aminin concentration became higher, minor binding oc-
urred. This is perhaps due to the above-mentioned
bility of a3b1 to bind laminin with low affinity (Ziober et
l., 1996).
xpression of a6 results in binding of VLPs
We next wished to ascertain if the expression of a6
ntegrin in DG75 cells would result in the acquisition of
he ability to bind PV particles. The cells were incubated
ith VLPs at 4°C before being extensively washed and
irus attachment determined by Western blotting using
FIG. 4. Cell adhesion assays. DG75 control and a6-expressing cells
ere plated onto laminin-coated tissue culture wells and incubated for
0 min before being washed and stained with crystal violet, and the
D600 was read.n L1 monoclonal antibody. It can be seen that the wxpression of a6 confers upon the DG75 cells the ability
o bind PV particles, whereas control cells were not able
o bind (Fig. 5A). Positive control A431 cells were able to
ind PV particles, although the smaller amount of binding
bserved is due to the fact that five times fewer A431
ells were used. Flow cytometry analysis clearly indi-
ates that A431 cells express higher levels of a6 than
G75-a6 cells (Fig. 2). In order to determine if VLPs were
ndeed attaching via a6 we undertook to block binding
sing an anti-a6 antibody, GoH3. We have previously
hown that GoH3 is able to block binding of VLPs to
aCaT cells (Evander et al., 1997). The addition of GoH3
as able to inhibit the binding of VLPs to DG75-a6 cells
o background levels, therefore indicating that binding
as occurring via the a6 integrin (Fig. 5B).
DISCUSSION
The data presented here show that the a6 integrin is
oth necessary and sufficient for PV VLP binding and
hat VLP–cell interaction was totally inhibited by a6 an-
ibodies. The fact that no binding was observed in the
resence of a6 antibodies meant studies to ascertain if
his block also inhibited PV infection could not be under-
aken. Integrins have been shown previously to act as
irus receptors for initial binding and/or internalization,
s in the case of echovirus (a2b1) (Bergelson et al.,
FIG. 5. Binding of HPV6b L1 VLPs to cells detected by immunoblot-
ing for L1 protein. (A) Cells were treated with (1) or without (2) VLPs,











































































































276 MCMILLAN ET AL.992), coxsackievirus (avb3) (Roivainen et al., 1994), han-
avirus (b3) (Gavrilovskaya et al., 1998), adenovirus
avb3/5) (Wickham et al., 1993), and foot and mouth
isease virus (avb3) (Berinstein et al., 1995). However,
inding and/or internalization by viruses through avb3
ntegrins requires a virally encoded RGD motif and vi-
uses containing an RGD motif were inhibited by RGD
eptides. PVs do not have an RGD motif and PV VLP
inding is not inhibited in this manner. PVs and hanatvi-
us are the only viruses so far to bind via an RGD-
ndependent mechanism.
Here we show that cell lines that express either a6b1
r a6b4 bind VLPs. This indicates that the beta partner is
ot important for the binding of VLP to a6 and agrees
ith previous data showing that anti-a6 antibodies block
he binding, while anti-b1 or -b4 antibodies do not
Evander et al., 1997). Integrins are dual receptors for
xtracellular matrix and cytoskeletal proteins and al-
hough the exact role of the a6 subunit has not been
scertained the b4 subunit has been shown to associate
ith the keratin filament system (Spinardi et al., 1993)
nd mediates signal transduction (Mainiero et al., 1997).
owever, studies indicate that within integrins both a
nd b subunits contribute to ligand binding (Shih et al.,
997). This would imply that the beta subunit does not
hare contact residues for PV VLPs (or contacts are not
mportant for binding) or that the monoclonal antibodies
gainst them do not interfere with binding. The a6b1
ntegrin is expressed on a wide range of cells, including
latelets, lymphocytes, macrophages, oocytes, and en-
othelial cells, whereas a6b4 is relatively restricted to
pithelial, mesenchymal, and some neuronal cells. The
act that VLPs bind to a6b1 may therefore explain the
ide range of cells that PVs are reported to be able to
ind. However, it is clear that while PVs bind to a wide
ange of cells there is no clinical infection of these cell
ypes.
It has recently been reported that VLPs from HPV type
1 interact with heparin and other cell surface glycos-
minoglycans (Joyce et al., 1999). This report seems in
onflict with a previous report showing that inhibition of
lycosaminoglycan synthesis has no effect on VLP bind-
ng (Qi et al., 1996), although this may reflect the use of
ifferent assays. However, binding of papillomavirus
LPs to the a6 integrin does not rule out an initial
nteraction with glycosaminoglycans and it is possible
hat other receptors exist or that proteoglycans and in-
egrins act in concert to facilitate HPV uptake. Although
-cells are known to express heparin it would be of
xtreme interest to know the status of glycosaminogly-
ans on DG-75 cells.
Our data indicate that it is possible to express a6
ntegrin within a B-cell, which has not been previously
eported. The a6 expressed in DG75 cells functioned in
normal fashion in that it was expressed on the cell
urface and was partnered with b1, and transfected cells 1ere able to attach to plates coated with laminin,
hereas control cells were not.
The molecular basis for the strict tissue and species
ropism of PV is unknown. The receptors for several
iruses have been shown to be the sole determinants of
heir cell tropism (Brown et al., 1993; Haun et al., 1993).
owever, in the case of PV the wide distribution of a6
ntegrin and PV binding are clearly not matched by any
roductive replication in these cells. Therefore the tro-
ism of PVs must be at a step downstream of binding,
uch as uptake, transport to the nucleus, uncoating,
ranscription/translation, DNA replication, assembly, or
elease. The identification of the a6 integrin as a PV
eceptor does not exclude the fact that there may be
ther receptors or even coreceptors, although our previ-
usly published data indicate that pretreatment of cells
ith laminin, the a6 ligand, inhibits virus binding, sug-
esting further that the a6 integrin is a primary attach-
ent receptor (Evander et al., 1997). However, many
iruses are known to require a second receptor to facil-
tate virus uptake (e.g., chemokine receptors for HIV or
vb3/5 for adenovirus). We are actively pursuing this
ossibility.
There is a paucity of detail regarding the interaction of
V and its receptor, although some conclusions can be
rawn from antibody studies. All neutralizing antibodies
hown to block PV infection (by xenograft, foci formation,
r early-gene PCR) recognize only conformational viral
pitopes (Christensen et al., 1994, 1996; Roden et al.,
996). Furthermore, serum raised against denatured
LPs is not protective, indicating that any domain upon
V that inhibits infection is likely to be nonlinear. Inter-
stingly, these neutralizing antibodies are highly type-
pecific, despite the high degree of sequence conserva-
ion in L1 genes, a fact that appears to be inconsistent
ith the data indicating that all PVs tested so far interfere
ith the ability of PVs from another species or type to
ind to cells. One could speculate therefore that the PV
nteraction with a6 can occur in two ways; either a
iverse range of epitopes exist upon different PV sub-
ypes which all recognize a6 or there is a single, highly
onserved, a6 binding epitope upon all PVs in addition to
n epitope(s) that interacts with a secondary receptor to
acilitate binding and/or uptake. The latter possibility
ppears the more likely. Indeed, it has been shown that
eutralization occurs by more than one mechanism.
ome antibodies to L1 can prevent virions from binding
o the cell surface, presumably by blocking binding to a
eceptor (Roden et al., 1994b), possibly the a6 integrin.
ther neutralizing L1 antibodies do not inhibit PV bind-
ng, yet efficiently prevent infection (our unpublished data
nd Booy et al., 1998; Christensen et al., 1995). One
uggested mechanism for the neutralizing activity of
hese antibodies is the prevention of uncoating and in-





























































































277EXPRESSION OF THE a6 INTEGRIN CONFERS HPV BINDINGThe elucidation of a6 integrin as both necessary and
ufficient for PV VLP binding will allow the above hypoth-
sis to be tested. Furthermore, it identifies a potential
herapeutic target with which to block PV infection. Fi-
ally, the a6 integrin is known, upon ligand binding, to
nvoke a signal transduction pathway to initiate DNA
eplication in keratinocytes, a situation that would be
dvantageous for viral replication. The role that the re-
eptor/virus ligation on the cell surface plays in prepar-
ng the cell for viral infection can now be addressed.
METHODS AND MATERIALS
LPs, cell lines, and antibodies
HPV type 6b L1 VLPs were produced in Sf9 cells by
sing HPV6b L1 recombinant baculovirus and purified as
reviously described (Qi et al., 1996). DG75 cells, an
BV-negative, Burkitt’s lymphoma B-cell line, was pro-
ided by Dr Ihor Misko, Queensland Institute of Medical
esearch, Brisbane, Australia. HaCaT human epithelial
ells were a gift from Dr Nobert Fusenig, Deutsches
rebsforschungszentrum, Heidelberg, Germany. A431
nd Cos-7 cells were obtained from the American type
ulture Collection. The following antibodies were used:
nti-a6 (GoH3), Serotec, England; anti-b1 (P5D2), a gift
rom Elizabeth Wagner, University of Minnesota; anti-
PV16-L1 (Mab-8), a gift from Dr. Stephan Kelsall, De-
artment of Microbiology, University of Western Austra-
ia; and anti-b4 (3E1), Gibco-BRL, USA.
inding assays
Adherent cells were detached from plates using 0.25%
rypsin-0.02% EDTA, resuspended in complete DMEM
nd held in suspension for 60 min to allow re-expression
f surface antigens. Cells were washed twice in ice cold
inding medium (DMEM plus 0.2% BSA) and resus-
ended in 200 ml of binding medium. If a blocking assay
as performed the cells were then incubated for 60 min
n ice with the appropriate antibodies (as indicated)
efore being washed twice with binding media. VLPs
ere added to cells as indicated and incubated on ice
or a further 90 min. Cells were washed extensively with
ce cold PBS, resuspended in SDS-PAGE loading buffer,
oiled for 10 min, and loaded on an SDS-polyacrylamide
el.
mmunoblotting
Proteins separated on SDS- polyacrylamide gels were
lectrically transferred (100V, 60 min) to nitrocellulose
ilters before being blocked with PBS-0.05% Tween 20
PBST) plus 5% skim milk powder for 60 min at room
emperature. Antibodies were added as indicated and
ncubation continued for 60 min. Blots were washed 3
imes with PBST and HRP-conjugated anti-species anti-
ody were added and incubation continued for a further t0 min. The blots were washed 4 times with PBST before
etection using enhanced chemiluminescence (Amer-
ham, UK) according to the manufacturer’s instructions.
loning of a6 and transfection of DG75 cells
The 3.5-kbp cDNA for the a6A gene (a kind gift from
ito Quaranta, Scripps Institute) was excised with Not1
nd cloned into the Not1 site of EBO-pLPP (Margolskee
t al., 1988). This vector encodes the EBV origin of rep-
ication allowing stable, episomal replication of the plas-
id in B cells, while expression of a6A was driven off the
V40 early promoter. The resulting clone was transfected
nto cells by electroporation. Briefly, 5 3 106 cells were
ixed in a 0.4-cm electroporation curvette with 10–20mg
f DNA in a total volume of 250 ml of complete DMEM
nd incubated for 5 min at room temperature before
eing electroporated at 230V, 960mF, and Ohms limited
o 200 using a BioRad Gene Pulser. Following electropo-
ation the cells were allowed to stand for 5 min before
eing added to 5ml of complete DMEM and incubated
or 48 h. Transfected cells were then cultured in selective
edia (complete DMEM plus 600mg/ml hygromycin B).
xpression was confirmed by flow cytometry.
dhesion assay
Cell matrix proteins (human laminin or fibronectin)
ere diluted in PBS to the indicated concentrations and
00 ml placed into 96-well plates and incubated over-
ight at 4°C. The wells were blocked with 100ml of
MEM supplemented with 1% BSA for 1 h at 37°C. Cells
ere centrifuged, resuspended in DMEM/1% BSA and
dded in triplicate (1 3 105 per well in a 100ml volume).
ells were incubated at 37°C for 1 h before being
ashed 3 times with DMEM/1% BSA and fixed with 100%
ethanol for 10 minutes. The adherent cells were
tained with a solution of 0.2% crystal violet in 2% ethanol
or 5 minutes and washed extensively in water before the
tain was solubilized in 100ml of 1% SDS and OD600 was
ead.
125I labeling of cells
Cells were surface labeled in suspension with 125I
ICN, Australia) using Iodo-beads (Pierce, Australia).
riefly, cells (1–2 3 106) were resuspended in PBS and
ncubated with Iodo-beads and 125I (100mCi) for 15 min at
oom temperature. The beads were removed and the
ells washed 3 times with PBS before being solubilized
n lysis buffer (1% NP-40, 20mM Tris-HCl pH 5 7.5,
00mM NaCl, 4mM EDTA, 1mM PMSF) for 30 min at 4°C.
he lysates were clarified by centrifugation at 14000 xg
or 1 min and used in immunoprecipitation experiments.
mmunoprecipitation of 125I-labeled integrins
Cell lysates were precleared by incubation with pro-














































278 MCMILLAN ET AL.ade up to 500ml with PBS before anti-integrin antibod-
es were added and the mixture rotated at 4°C for 60 min.
rotein G–Sepharose was added and the tubes mixed
or a further 45 min at 4°C. Immune complexes were
ashed 3 times with PBS before the addition of SDS–
AGE loading buffer, boiled for 10 min, and analyzed by
DS–PAGE.
low cytometry
Analysis of expression of cell surface molecules by
low cytometry was performed as previously described
Qi et al., 1996).
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